Register Login

FOGHORN THERAPEUTICS INC. (FHTX)

(80% Positive) FOGHORN THERAPEUTICS INC. (FHTX) Announces Enrollment Update for escalation Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 7, 2026, 11:04 a.m.

    📋 FOGHORN THERAPEUTICS INC. (FHTX) - Clinical Trial Update

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 07:01:52

    Event Type: Clinical Trial Update

    Event Details:

    FOGHORN THERAPEUTICS INC. (FHTX) Announces Clinical Trial Update FOGHORN THERAPEUTICS INC. (FHTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: escalation, filing
    • Diseases/Conditions: oncology
    • Clinical Stage: Phase 1
    • Collaboration: GLOBE NEWSWIRE
      • anticipated in 2026
      • expected IND in 2027
      • targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical and preclinical programs, including the ongoing Phase 1 trial evaluating FHD-909 in SMARCA4-mutated cancers, selective CBP and selective EP300 degrader programs, selective ARID1B degrader program and other preclinical product candidates, expected timing of clinical data, expected cash runway, expected timing of regulatory filings, and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025

    🔬 Clinical Development Pipeline (FOGHORN THERAPEUTICS INC.):

    Product Type Development Stage Therapeutic Area Source
    FHD-286 Other Phase PHASE1 Metastatic Uveal Melanoma ClinicalTrials.gov
    FHD-609 Other Phase PHASE1 Advanced Synovial Sarcoma ClinicalTrials.gov
    Decitabine Other Phase PHASE1 Advanced Hematologic Malignancy ClinicalTrials.gov
    Low Dose Cytarabine Other Phase PHASE1 Advanced Hematologic Malignancy ClinicalTrials.gov
    Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: FOGHORN THERAPEUTICS INC.
    • Ticker Symbol: FHTX

Search

News categories